FAQS
The Nation Eye Institute (NEI) and American Academy of Ophthalmology (AAO) Preferred Practice Pattern Guidelines advise against the AREDS formulas for early stage AMD.
AREDS Report #8 indicated potential harm from zinc use by early AMD patients. (Chew, 2001)
Some individuals will experience harmful results from taking zinc due to a common AMD genetic risk profile. Only the VitaRisk genetic test can identify people who should avoid high-dose zinc supplements. (Kaufman, 2020) (Vavvas, 2018) (Seddon, 2016) (Awh, 2014, 2013)
The best choice for early stage retinal conditions is a macular pigment carotenoid formula containing lutein, zeaxanthin, and meso-zeaxanthin.
Similar to AMD, the diabetic retina can be characterized by:
Increasing the Macular Pigment Density in diabetic eyes is known to improve visual function. (Hu, 2016) (Garcia-Medina, 2016) (Roig-Revert, 2015) (Moschos, 2017)
Vision Essence Early Defence is formulated with all three macular protective pigments known to increase macular pigment volume.
AMD genetic testing is the only safe way to consume zinc containing eye vitamins. (Kaufman, 2020) (Vavvas, 2018) (Seddon, 2016) (Awh, 2014, 2013)
Supplementation trials with lutein, alone, have shown only modest results in increasing macular pigment volume (MPD). Studies which included meso-zeaxanthin demonstrated more rapid and robust increases in MPD. (Ma, 2016)